Muscle loss from a course of corticosteroids, or from weeks in a cast or a hospital bed, is a different problem from the slow muscle loss of ageing. Different trigger, different time course, and a different experimental literature. The ageing question has its own page. This one is about the acute kind. Hospital medicine turns up elsewhere on the site too: TUDCA was given to neonates on parenteral nutrition in a randomised comparison.
One clarification belongs at the top, because this site attracts readers from both directions. The steroids that cause this type of muscle wasting are corticosteroids such as dexamethasone and prednisone, prescribed for inflammation. They are not anabolic steroids, which do the opposite to muscle and raise an entirely separate set of liver concerns covered on the oral steroid cycle page. Conflating the two is the most common error in this area.
Key Takeaways
- In mice given dexamethasone, TUDCA improved muscle atrophy and weakness, measured as increased grip strength and longer running time to exhaustion[1].
- The mechanism was traced to the Akt/mTOR/S6K pathway and inhibition of FoxO3a, lowering the muscle-wasting genes MuRF1 and Atrogin-1. Blocking Akt abolished the effect, which is a proper mechanistic test rather than a correlation[1].
- In mice subjected to hindlimb unloading, oral TUDCA at 500 mg/kg/day attenuated muscle atrophy and the rise in ubiquitin ligases through the same AKT and FoxO3a pathway, and prevented the shift in myofibre type[2].
- In a mouse model of statin myopathy, TUDCA blocked the unfolded protein response markers and significantly improved the statin-driven loss of muscular endurance[3].
- A safety signal runs the other way. In two mouse models of Duchenne muscular dystrophy, TUDCA in drinking water for four weeks increased ectopic calcification, and only in muscles lacking dystrophin[4].
- All of the above is rodent work. No human trial has tested TUDCA for muscle atrophy of any cause.
Why Muscle Wasting Is an ER Stress Question
Skeletal muscle atrophy is a balance problem: protein degradation outpaces protein synthesis. The degradation side runs largely through two muscle-specific ubiquitin ligases, MuRF1 and Atrogin-1, which are switched on by the transcription factor FoxO3a. Anything that keeps FoxO3a quiet, or keeps the Akt pathway active, tilts the balance back.
The link to endoplasmic reticulum stress was made directly in a 2023 study. Mice underwent 3, 7 or 14 days of hindlimb unloading, and rhesus macaques underwent six weeks of head-down tilted bed rest. ER stress marker genes rose rapidly with unloading, on a similar trajectory to Atrogin-1, MuRF1 and MUSA1[2]. That established the stress response as a feature of disuse atrophy rather than an incidental finding. Prolonged disuse is also the downstream problem after a spinal cord injury, and the same endoplasmic reticulum stress response is traced through other tissues on this site, including the brain in the context of mood.
What Happened When the Stress Was Blocked
In the same study, TUDCA was administered orally at 500 mg/kg/day during unloading as a pan-ER stress inhibitor. It attenuated the atrophy and the upregulation of the ubiquitin ligases via the AKT and FoxO3a pathway. It also inhibited the shift from oxidative to glycolytic myofibre type that unloading produces[2]. The fibre type result is worth flagging separately, because it is a structural change rather than a mass measurement.
The corticosteroid work is more detailed. A 2021 study looked at dexamethasone in both C2C12 myotubes and mice. In culture, TUDCA improved the differentiation index and the expression of myogenin and myosin heavy chain, activated Akt/mTOR/S6K signalling, inhibited FoxO3a transcriptional activity and cut MuRF1 and Atrogin-1[1].
Then the authors did the experiment that makes the claim testable. They blocked Akt with MK2206, and the protective effects of TUDCA on the myotubes disappeared[1]. A mechanism you can abolish by blocking one node is a much stronger result than a list of markers that moved in the right direction.
In the mice, TUDCA improved dexamethasone-induced atrophy and weakness with two functional readouts rather than tissue weights alone: grip strength increased and running time to exhaustion lengthened, alongside suppressed apoptosis, reduced protein degradation and increased protein synthesis[1].
The Statin Myopathy Line
A related result comes from statin-induced muscle damage, which is a common enough clinical problem to be worth knowing about. Atorvastatin and simvastatin activated unfolded protein response markers including ATF6, CHOP and spliced XBP1 in muscle cells, and TUDCA inhibited both those markers and the cleavage of PARP-1 and caspase-3[3].
In mice given statins, muscular endurance fell, and that reduction was significantly improved in the TUDCA-treated group. Mice deficient in CHOP were similarly protected, which supports ER stress as the route by which statins damage muscle rather than a bystander[3].
The obvious inference, that someone with statin-related muscle aches should add TUDCA, is not supported by this. It is a mouse study with a mechanistic endpoint, statin myopathy in people has established management, and TUDCA has its own interaction considerations worth reading before stacking it onto a cardiovascular drug.
The Finding That Points the Other Way
A 2025 study set out to test a reasonable hypothesis and got the opposite of what it predicted. Dystrophic muscle calcifies, ER stress is thought to contribute, and TUDCA suppresses ER stress, so TUDCA should reduce mineral deposits. Four-week-old mdx mice, mdx-betageo mice and wild-type controls were given TUDCA in drinking water for four weeks, then scanned whole-body after tissue clearing and alizarin staining[4].
TUDCA enhanced calcification of dystrophic muscles. It did not do so in dystrophin-positive muscles, it did not affect the elevated ER stress markers, and it did not change the pro-calcifying proteins RUNX2, Osterix and BMP2/4 or alkaline phosphatase activity. The effect was specific to muscles lacking dystrophin and, on the authors reading, was not driven by the ER stress pathway at all[4].
Two things follow. The narrow one is that anyone with a dystrophinopathy has a concrete reason to raise this with a neuromuscular specialist before taking TUDCA. The broader one is that “suppresses ER stress” is not a universal good. In this tissue, under this condition, a compound given for protection made one measurable feature of the disease worse.
What Would Have to Be True for This to Matter in a Person
The doses are the first obstacle. 500 mg/kg/day in a mouse is not a scaled version of a human capsule, and the one place a real human dose has been studied over months is a multiple sclerosis trial, where 2 g/day for 16 weeks was safe and well tolerated but moved no clinical endpoint[5]. Tolerability at that dose is useful to know. It is not evidence of a muscle effect.
The second obstacle is that the ageing literature, where TUDCA has its best muscle result, does not transfer. Treating 18-month-old mice for 20 days increased skeletal muscle mass, restored fibre size, improved insulin sensitivity through AKT activation and raised protein synthesis markers[6]. That is a different trigger and a different time course from a course of prednisone or three weeks in a cast.
The third is that resistance exercise and protein intake have human outcome data for preserving muscle during and after these insults, and a bile acid does not. Nothing on this page is medical advice, and a prescribed corticosteroid course is not something to modify around a supplement.
Frequently Asked Questions
Does TUDCA prevent muscle loss from prednisone or dexamethasone?
In mice, it reduced dexamethasone-induced atrophy and improved grip strength and running endurance, working through Akt/mTOR/S6K and FoxO3a[1]. No human study has tested this. Prednisone and dexamethasone are prescribed for reasons that outweigh muscle effects, and the course should not be altered around a supplement.
Would it help during a period of immobilisation?
Unknown in humans. Oral TUDCA at 500 mg/kg/day attenuated atrophy in hindlimb-unloaded mice and prevented the oxidative to glycolytic fibre shift[2]. The primate arm of that study was used to characterise the ER stress response, not to test the drug.
Is this relevant to anabolic steroid users?
No. This literature concerns corticosteroids, which cause muscle wasting. Anabolic steroids do not, and the reason TUDCA comes up in that context is liver support, covered on the steroid cycle page.
Is there any reason not to take TUDCA for muscle?
One specific one. In two mouse models of Duchenne muscular dystrophy, TUDCA increased ectopic calcification in muscles lacking dystrophin, an effect not seen in normal muscle and not explained by ER stress[4]. Anyone with a muscular dystrophy should treat that as a question for a specialist rather than a footnote.
References
- Administration of tauroursodeoxycholic acid attenuates dexamethasone-induced skeletal muscle atrophy. Biochem Biophys Res Commun (2021).
- ER Stress is Activated and Involved in Disuse-Induced Muscle Atrophy. Front Biosci (Landmark Ed) (2023).
- C/EBP homologous protein deficiency inhibits statin-induced myotoxicity. Biochem Biophys Res Commun (2019).
- Tauroursodeoxycholic acid-induced increase in ectopic muscle mineralization occurs exclusively in dystrophic muscles and is independent of endoplasmic reticulum stress. Sci Rep (2025).
- Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease. Med (2025).
- Tauroursodeoxycholic acid (TUDCA) ameliorates age-related skeletal muscle loss. J Physiol (2026).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
